Symbols

BEAM

Beam Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

Significant Net Income Growth

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BEAM

Beam Therapeutics Inc.

A company that developing DNA base editing and gene editing technologies

Industry

Biological Technology

Established Date

01/25/2017

Listing Date

02/06/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

511

Fiscal Year Ends

12-31

Website

www.beamtx.com

Security Type

Common stock

Office address

238 Main Street, Cambridge, MA 02142

Business

Introduction

Founded on January 25, 2017, Beam Therapeutics Inc., is a biotechnology company dedicated to creating a new class of precision genetic medicines based on its proprietary base editing technology, with the vision of providing lifelong treatment for patients suffering from serious diseases.

Company Financials

EPS

BEAM has released its 2025 Q4 earnings. EPS was reported at 2.33, versus the expected -1.01, beating expectations. The chart below visualizes how BEAM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BEAM has released its 2025 Q4 earnings report, with revenue of 114.11M, reflecting a YoY change of 279.52%, and net profit of 244.30M, showing a YoY change of 370.38%. The Sankey diagram below clearly presents BEAM's revenue sources and cost distribution.